Safety study of CITY-FXI in healthy adults and those with clotting risks
Part of Blood & lymphatic clinical trials.
This trial tests a new medicine, CITY-FXI, to see if it is safe and how it works in the body. It is for healthy adults and also for adults with specific genetic conditions (Factor V Leiden or Prothrombin G20210A mutation) that increase the risk of blood clots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 45 years old (for Part A) or between 18 and 60 years old (for Part B).
- Your body mass index (BMI) must be between 18 and 25, and you must weigh at least 50 kg (about 110 pounds).
- You need to be willing to follow all study procedures and lifestyle rules.
- For Part B: You must have a confirmed genetic diagnosis of Factor V Leiden or Prothrombin G20210A mutation.
- For Part B (if female and able to become pregnant): You must agree to use highly effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps researchers learn more about two inherited blood-clotting conditions: Factor V Leiden and Prothrombin G20210A mutations. By participating, you'll help doctors better understand these conditions and how they affect people's health.
This is an early-stage safety study testing a new experimental medicine that affects blood clotting in people with no serious health conditions. Researchers want to make sure the medicine is safe and well-tolerated before testing it in patients who need it.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
This study tests how well and how safely Octapharma’s clotting factor products (Nuwiq, Octanate, or Wilate) work in people with Hemophilia A who are newly treated or have had very few clotting factor doses. It also looks at how often side effects occur and how the treatments are used in real care.
This trial tests a drug called VMX-C001 to quickly reverse the effects of certain blood thinners (Factor Xa inhibitors) in people who need urgent surgery with a high risk of bleeding. It compares VMX-C001 to standard care to see which is more effective at helping blood clot normally.
This Phase 1/2 study tests VGA039 in healthy adults and people with von Willebrand disease (VWD). The goal is to see if the drug is safe and how it affects bleeding-related factors, especially in people who have symptoms.
Hear when a new Factor V Leiden trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.